In this platform, epidermal growth factor receptor (EGFR) is used as the targeting molecule, gadolinium chelate as the magnetic resonance imaging contrast agent, polyamidoamine (PAMAM) and 3,3′-dithiobis (sulfosuccinimidyl propionate) as the response agents of intratumoral glutathione, 5-fluorouracil (5Fu) and cetuximab as drug payloads, and the pH as the release stimulus for the combined diagnosis and treatment of nasopharyngeal carcinoma (NPC) using SeNPs. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.